DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/94606a50/cervical_cancer) has announced the addition of Global Markets Direct's new report "Cervical Cancer - Pipeline Review, H1 2012" to their offering.
Global Markets Direct's, 'Cervical Cancer - Pipeline Review, H1 2012', provides an overview of the Cervical Cancer therapeutic pipeline. This report provides information on the therapeutic development for Cervical Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cervical Cancer. 'Cervical Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Key Topics Covered:
- Introduction
- Global Markets Direct Report Coverage
- Cervical Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Cervical Cancer
- Cervical Cancer Therapeutics under Development by Companies
- Cervical Cancer Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Cervical Cancer Therapeutics - Products under Development by Companies
- Cervical Cancer Therapeutics - Products under Investigation by Universities/Institutes
- Companies Involved in Cervical Cancer Therapeutics Development
- Cervical Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Cervical Cancer Therapeutics - Drug Profile Updates
- Cervical Cancer Therapeutics - Discontinued Products
- Cervical Cancer Therapeutics - Dormant Products
- Cervical Cancer - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
Companies mentioned:
- Helix BioPharma Corp.
- Sanofi-Aventis
- GlaxoSmithKline plc
- Inovio Biomedical Corporation
- Merck & Co., Inc.
- YM BioSciences Inc.
- MediGene AG
- Novartis AG
- Taiho Pharmaceutical Co., Ltd.
- Zeria Pharmaceutical Co Ltd
- CEL-SCI Corporation
- Advaxis, Inc.
- 3SBio Inc.
- Neogenix Oncology Corporation
- Dendreon Corporation
- Transgene SA
- Antigen Express, Inc.
- Nutri Pharma ASA
- ApoImmune, Inc.
- PDS Biotechnology Corporation
- BT PHARMA
- PharmaMar, S.A.
- Genetic Immunity, LLC
- Advanced Cancer Therapeutics
- Eurofarma
- ISA Pharmaceuticals B.V.
For more information visit http://www.researchandmarkets.com/research/94606a50/cervical_cancer
Source: Global Markets Direct